Category: CovidienSyndicate content

Failure of Medtronic's Symplicity-3 trial doesn't mean the end of renal denervation for hypertension | Medtech Wall Street news for the week of September 1, 2014

September 4, 2014 by MassDevice

Here's a look at some of the top Wall Street stories for medical device companies this week: Renal denervation isn't dead, despite Medtronic trial's failure; Baxter says HQ will stay in Illinois, stays coy on Boston plans; Private equity owners rebrand KCI, Systagenix, LifeCell as Acelity

Renal denervation isn't dead, despite Medtronic trial's failure

September 2, 2014 by Brad Perriello

Covidien acquires Sapheon and its VenaSeal device | The week in medtech M&A

September 3, 2014 by MassDevice

Here's a look at some of the top regulatory stories for medical device companies this week: Covidien acquires Sapheon and its VenaSeal varicose vein treatment; Medtronic to cover $58M tax tab for top execs in Covidien buy; Report: J&J puts Cordis on the block; Another Covidien shareholder sues over Medtronic deal; Allergan accedes to special meeting, asks court to block Valeant's vote

Covidien acquires Sapheon and its VenaSeal varicose vein treatment

August 28, 2014 by Brad Perriello

Medtech trends: The most talked about device makers in August 2014

September 3, 2014 by Arezu Sarvestani

MassDevice.com looks at the internet chatter surrounding the medical device industry with some of most searched-for companies of the last month.

chart

Click to enlarge.

MassDevice.com looked at some of the most talked-about medical device companies, based on trends in U.S. Google searches for the last 30 days.

Renal denervation isn't dead, despite Medtronic trial's failure

September 2, 2014 by Brad Perriello

The failure of Medtronic's Symplicity 3 trial doesn't mean the end of renal denervation in treated resistant hypertension, especially in Europe, but future studies face a high bar set by the Medtronic trial's sham control arm.

Renal denervation isn't dead, despite Medtronic trial's failure

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

ArthroCare executives found guilty of defrauding investors | Medtech legal news for the week of September 1, 2014

September 1, 2014 by MassDevice

Here's a look at some of the top legal news stories for medical device companies this week: ArthroCare ex-CEO faces 30-year sentence for fraud; Shareholders sue Edap following FDA slip; Ex-sales rep wins class action status in lawsuit against Stryker; Another Covidien shareholder sues over Medtronic deal; Respiratory rivals ResMed, BMC each tally wins in Trade Commission ruling

ArthroCare ex-CEO faces 30-year sentence for fraud

August 25, 2014 by Arezu Sarvestani

ArthroCare ex-CEO faces 30-year sentence for fraud

Medtronic to cover $58M tax tab for top execs in Covidien buy

August 29, 2014 by Brad Perriello

Medtronic reveals that the tax tab for its top executives from its Covidien buyout will near $58 million, apart from the capital gains taxes all shareholders will pay on the $43 billion deal.

Medtronic to cover $58M tax tab for top execs in Covidien buy

Covidien acquires Reverse Medical | Medtech Wall Street news for the week of August 25, 2014

August 28, 2014 by MassDevice

Here's a look at some of the top Wall Street stories for medical device companies this week: Covidien snaps up Reverse Medical; Standard & Poor's maintains credit watch on Medtronic over Covidien buy; Allergan can't delay shareholder vote on hostile Valeant bid; Medtronic drops $200M on Dutch DBS firm Sapiens; Nobel Biocare's Q2 profits double as it fields buyout interest

Covidien snaps up Reverse Medical

August 22, 2014 by Brad Perriello

YYmeta
Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp